Sequential topoisomerase I (topo I) and topoisomerase II (topo II) inhibitors in relapsed/refractory aggressive NHL: Results of CALGB 59906, a phase II study of doxorubicin and topotecan.

被引：0
|
作者：
Smith, SM
Johnson, JL
Niedzwiecki, D
Eder, JP
Canellos, GP
Cheson, BD
Bartlett, NL
机构：
[1] Univ Chicago, Dept Med, Chicago, IL 60637 USA
[2] Duke Univ, Canc & Leukemia Grp B, Ctr Stat, Durham, NC USA
[3] Dana Farber Canc Inst, Boston, MA 02115 USA
[4] Georgetown Univ, Vincent T Lombardi Canc Res Ctr, Washington, DC 20007 USA
[5] Washington Univ, St Louis, MO USA
来源：
BLOOD | 2004年 / 104卷 / 11期
关键词：
D O I：
10.1182/blood.V104.11.2500.2500
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2500
引用
收藏
页码：685A / 686A
页数：2
相关论文
共 50 条
  • [21] Sequencing topotecan and etoposide plus cisplatin to overcome topoisomerase I and II resistance: A pharmacodynamically based phase I trial
    Aisner, J
    Musanti, R
    Beers, S
    Smith, S
    Locsin, S
    Rubin, EH
    CLINICAL CANCER RESEARCH, 2003, 9 (07) : 2504 - 2509
  • [22] Studies on the drug against refractory diseases. Part I - Synthetic inhibitors of DNA topoisomerase I and II
    Katayama, H
    Kawada, Y
    Kaneko, K
    Oshiyama, T
    Takatsu, N
    CHEMICAL & PHARMACEUTICAL BULLETIN, 1999, 47 (01) : 48 - 53
  • [23] Phase I study of OSI-211, a novel liposomal topoisomerase 1 (Topo 1) inhibitor, in patients with refractory leukemia
    Apostolidou, E
    Garcia-Manero, G
    Cortes, J
    Thomas, D
    Andreeff, M
    Keating, M
    Tallman, M
    Kantarjian, H
    Giles, F
    BLOOD, 2002, 100 (11) : 262B - 262B
  • [24] Phase I/II Study of Dasatinib In Relapsed or Refractory Non-Hodgkin's Lymphoma (NHL)
    William, Basem M.
    Hohenstein, Maribeth
    Loberiza, Fausto R., Jr.
    Caponetti, Gabriel C.
    Bociek, R. Gregory
    Bierman, Philip
    Armitage, James O.
    Chan, Wing-Chung
    Vose, Julie M.
    BLOOD, 2010, 116 (21) : 131 - 131
  • [25] Survival impact of switching to different topoisomerase I or II inhibitors-based regimens (topo-I or topo-II) in extensive-disease small cell lung cancer (ED-SCLC): supplemental analysis from JCOG0509.
    Nomura, Shogo
    Umemura, Shigeki
    Yoh, Kiyotaka
    Shinozaki, Tomohiro
    Shibata, Taro
    Nakamura, Kenichi
    Satouchi, Miyako
    Ohe, Yuichiro
    Fukuda, Haruhiko
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [26] Convection-enhanced delivery of a topoisomerase I inhibitor (nanoliposomal topotecan) and a topoisomerase II inhibitor (pegylated liposomal doxorubicin) in intracranial brain tumor xenografts
    Yamashita, Yoji
    T Krauze, Michal
    Kawaguchi, Tomohiro
    Noble, Charles O.
    Drummond, Daryl C.
    Park, John W.
    Bankiewicz, Krystof S.
    NEURO-ONCOLOGY, 2007, 9 (01) : 20 - 28
  • [27] Combination of topotecan with cytarabine or etoposide in patients with refractory or relapsed acute myeloid leukemia: Results of a randomized phase I/II study
    Norbert Vey
    Hagop Kantarjian
    Miloslav Beran
    Susan O'Brien
    Jorge Cortes
    Charles Koller
    Elihu Estey
    Investigational New Drugs, 1999, 17 : 89 - 95
  • [28] Combination of topotecan with cytarabine or etoposide in patients with refractory or relapsed acute myeloid leukemia: Results of a randomized phase I/II study
    Vey, N
    Kantarjian, H
    Beran, M
    O'Brien, S
    Cortes, J
    Koller, C
    Estey, E
    INVESTIGATIONAL NEW DRUGS, 1999, 17 (01) : 89 - 95
  • [29] Phase II study of 131I-metaiodobenzylguanidine with 5 days of topotecan for refractory or relapsed neuroblastoma: Results of the French study MIITOP
    Sevrin, Francois
    Kolesnikov-Gauthier, Helene
    Cougnenc, Olivier
    Bogart, Emilie
    Schleiermacher, Gudrun
    Courbon, Frederic
    Gambart, Marion
    Giraudet, Anne-Laure
    Corradini, Nadege
    Badel, Jean-Noel
    Rault, Erwann
    Oudoux, Aurore
    Le Deley, Marie Cecile
    Valteau-Couanet, Dominique
    Defachelles, Anne-Sophie
    PEDIATRIC BLOOD & CANCER, 2024, 70 (11)
  • [30] Antiproliferative and apoptosis-inducing activities of novel naphthalimide-cyclam conjugates through dual topoisomerase (topo) I/II inhibition
    Tan, Shaoying
    Sun, Deheng
    Lyu, Jiankun
    Sun, Xiao
    Wu, Fangshu
    Li, Qiang
    Yang, Yiqi
    Liu, Jianxu
    Wang, Xin
    Chen, Zhuo
    Li, Honglin
    Qian, Xuhong
    Xu, Yufang
    BIOORGANIC & MEDICINAL CHEMISTRY, 2015, 23 (17) : 5672 - 5680
12345